10 Jan

Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

WRITTEN BY Daniel Collins

Recent approval

In December 2017, the European Commission (or EC) approved Roche’s (RHHBY) Alecensa (alectinib) as a monotherapy for the first-line treatment of individuals with anaplastic lymphoma kinase ALK-positive advanced NSCLC (non-small cell lung cancer). In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

ALEX trial

The EC approved Alecensa based on the results of the phase three ALEX trial. In the trial, Alecensa demonstrated a significant reduction in the risk of the disease worsening or death by 53% compared to crizotinib. In the phase three ALEX trial, Alecensa also demonstrated a reduction in the risk of tumors spreading to the brain or central nervous system by 84% compared to crizotinib.

During the trial, patients on Alecensa demonstrated median progression-free survival of 25.7 months, as evaluated by the Independent Review Committee compared to 10.4 months for patients on crizotinib.

Alecensa’s safety profile remained consistent with the prior studies and compared positively to Pfizer’s (PFE) Xalkori (crizotinib).

The EC converted the conditional marketing authorization of Alecensa in crizotinib failure to a complete standard marketing authorization. In November 2017, Alecensa received approval from the US FDA (Food and Drug Administration), Japan, and Turkey as a first-line treatment for individuals with ALK-positive NSCLC.

Alecensa’s peers include Takeda Pharmaceuticals’ (TKPYY) Alunbrig, Novartis’s (NVS) Zykadia, and Pfizer’s (PFE) Xalkori. The growth in sales of Roche’s Alecensa and Novartis’s Zykadia could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche and Novartis make up about ~0.69% and 0.79% of VEU’s total portfolio holdings, respectively.

Latest articles

McDonald’s (MCD) competition includes large international and national food chains as well as regional and local retailers of food products.

The restaurant industry is susceptible to a wide array of risks of macro and micro factors. As a huge global brand, McDonald’s faces several risks.

Google plans to offer a smart checking account along with Citigroup and Stanford Federal Credit Union. Tentatively called Cache, it could launch in 2020.

The proposed T-Mobile-Sprint merger agreement expired on November 1. Either company has the right to walk away from the transaction until a new date is set.

Since my last article about Nvidia (NVDA), the stock has risen from $196.86 to $208.57. I expect a further rise after today's earnings results.

TJX Companies (TJX) is scheduled to announce its fiscal 2020 third-quarter earnings results on November 19. Its third quarter ended on November 2.